Introduction
The Myc transcription factor servers as a master regulator in various biological processes through regulation of a large number of target genes, and the inappropriate expression of Myc is one of the most prevalent oncogenic events in human cancers (Dang, 1999; Meyer and Penn, 2008) . In addition to proteincoding genes, an increasing wealth of data showed that Myc can also modulate expression of microRNAs (miRNAs) (Chang et al., 2008; Gao et al., 2009; Ma et al., 2010 ) that function to inhibit target gene expression through 3 0 untranslated region (UTR) binding (Ambros, 2004) . Thus, an oncogenic role of Myc is expected to be achieved through regulating a complex gene network involving both activation of oncogenes and inactivation of tumor suppressors. Although miRNAs as Myc targets have been implicated in cancer development and progression (Chang et al., 2008; Gao et al., 2009; Ma et al., 2010) , there is limited understanding of their roles in the molecule pathways that are involved in the process of cellular transformation.
Oncogenic cooperation in tumorigenesis has long been recognized in transgenic mouse models in line with the notion that most human cancers are largely caused by summation of activated oncogenes and inactivated tumor suppressors (D'Cruz et al., 2001; Kendall et al., 2005) . Decades ago Sinn et al. (1987) demonstrated that the coexpression of c-MYC and v-H-ras oncogenes resulted in a strong synergy in mammary tumorigenesis. Although the concurrent activation of both oncogenes is anticipated to confer synergistic growth advantage, the molecular mechanism(s) underlying the potential cross talk between these two prominent oncogenic pathways remains to be fully elucidated.
Here, we identify a role of miR-378 at the crossroads between Myc and Ras signaling pathways in transformation. We demonstrate that miR-378 is a previously unrecognized Myc target that participates in oncogenic transformation through inhibition of TOB2 tumor suppressor candidate and subsequent transcriptional activation of cyclin D1.
Results

c-Myc directly transactivates miR-378 expression alongside its host gene PPARGC1B
In an attempt to identify miRNAs that are potentially involved in Myc-induced transformation, we examined the miRNA expression profile of human mammary epithelial cells MCF10A transformed by c-Myc (thereafter referred to as Myc) using Agilent human miRNA microarray system that contains probes for 866 human miRNAs. To this end, we identified 58 miRNAs that were differentially expressed in MCF10 cells that overexpress Myc as compared with MCF10A cells expressing an empty vector (using a twofold cut-off; Supplementary Table 1 and 2). The top nine genes showing at least a fivefold change were shown in Figure 1a . Among them, miR-378 shows the highest induction (11.4-fold). All six members of the miR-17-92 cluster, known to be Myc-inducible targets (He et al., 2005) , were also upregulated by Myc for 42-fold (also shown in Figure 1a , bottom), validating the system. Interestingly, miR-205 and miR-31, which have been recently identified as negative regulators of cancer epithelial-mesenchymal transition (EMT) and metastasis (Gregory et al., 2008; Korpal et al., 2008; Valastyan et al., 2009) , were also found to be strongly downregulated by Myc (Figure 1a ). This reveals a possibility that Myc might promote mesenchymal phenotype and metastasis through downregulation of miR-205 and miR-31.
We chose to focus on miR-378 in this study as it was the most strongly induced miRNA by Myc in this system and its role in oncogenic phenotype has not been previously studied. The miR-378 stem-loop is located in the first intron of PPARGC1B on chromosome 5 (Figure 1b) . Examination of a previously published data set containing genome-wide mapping of Mycbinding sites in human lymphoma cells through chromatin immunoprecipitation-PET analysis (Zeller et al., 2006 ) reveals a strong Myc binding at a 1.5 kb region upstream of miR-378 locus (Supplementary Figure 1a) . Sequence analysis using TFSEARCH (http://www.cbrc.jp) revealed four putative Myc-binding sites in this region, including two canonical (CACGTG) E-box motifs (Supplementary Figure 1b) , supporting that Myc may regulate the transcription unit containing miR-378 and its host gene PPARGC1B. Quantitative reverse transcription-PCR analysis validated this notion and showed that Myc overexpression induced strong inductions of miR-378 and PPARGC1B mRNAs (Figure 1c ). Myc box I deletion (dMbI) mutant, which is known to retain the transformation capacity and validated here by soft agar assay (Figure 1d ), still efficiently induced miR-378 expression. By contrast, Myc box II deletion mutant (dMbII), -1500 -500 HEK293T cells were transfected with pcDNA4, Myc or dMbII (100 ng), together with a luciferase reporter construct pGL4 (100 ng) containing the indicated genomic regions of miR-378/PPARGC1B promoter as show in b and an internal control construct pRL harboring renilla luciferase gene (Promega). Relative luciferase activities were measured 48 h after transfection. Results are presented as relative firefly luciferase activity after normalization to internal control renilla luciferase and pGL4 empty vector alone control. All experiments were performed at least twice in triplicate (nX6) *Po0.009. known to be defective in both transactivation and transformation (Conzen et al., 2000; Kuttler et al., 2001; Oster et al., 2003) , failed to do so.
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To further validate a role of Myc in transcriptional regulation of this genomic region, we cloned a 2.4 kb region containing the four Myc-binding motifs (F1) ( þ 1 to þ 2400) into pGL4 luciferase reporter construct. Another 1.0 kb DNA fragment (F2) that contains an upstream region of host gene PPARGC1B (À1500 to À500) was also cloned as a control. The results show that the F1, but not the F2, responded strongly to wildtype Myc, but not to dMbII mutant (Figure 1e ). These results validate Myc as a transactivator of PPARGC1B-miR-378 transcriptional unit.
Myc knockdown ablates the miR-378 expression in breast cancer cells To determine whether the above finding in Myctransformed MCF10A cells is relevant in human breast cancer cells, we performed Myc knockdown in a number of breast cancer cell lines. Treatment of these cells with three independent Myc small interfering RNAs (siRNAs) resulted in a marked decrease in both miR-378 and PPARGC1B expression levels ( Figure 2a) . Moreover, Myc knockdown in BT-549 and MDA-MB-231 cells diminished the activity of the luciferase reporter containing the F1, but not F2 (Figure 2b ). Collectively, these findings demonstrate a positive role for both exogenous and endogenous Myc in regulating miR-378 transcription in transformed breast epithelial cells. miR-378 cooperates with oncogenic Ras or HER2 to promote cellular transformation To determine a functional role of miR-378 in cellular transformation, we used a genetically defined immortalized human mammary epithelial cell line HMLE (human mammary epithelial cells expressing hTERT and SV40 large T) and HMLE expressing a low level of oncogenic HRAS (Val 12) that fails to induce full transformation (referred to as HMLER; Elenbaas et al., 2001) , a system often used to investigate the pathway interactions involved in cellular transformation. Retroviral miR-378 overexpression in HMLE cells did not yield significant effect on cell growth as assessed by either monolayer or soft agar, but resulted in strong induction of growth in HMLER cells (Figures 3a and b) . This suggests that miR-378 alone was insufficient, but required the cooperation of oncogenic Ras to induce transformation. Consistent with this notion, overexpression of HER2, an upstream signal of Ras, also synergized with miR-378 to promote anchorage-dependent and -independent growth in HMLE cells (Figures  3a and b) . This synergetic effect of miR-378 and Ras/ HER2 was also seen in MCF10A cells (Figure 3c ). In good accordance with the above findings, a similar effect of Myc in cooperation with Ras in promoting transformation was also seen in HMLE cells ( Figure 3d ). However, overexpression of miR-378 in above cell lines did not result in a significant increase in cell proliferation ( Supplementary Figure 2a) , suggesting that the effect of miR-378 on transformation is not simply a result of proliferation advantage. Further, this phenotypic change was not accompanied with enhanced activation of Ras or HER2 downstream signaling, such as mitogen-activated protein kinase (MAPK) and AKT in HMLER or HMLE-HER2 cells (Supplementary Figure 2b) , suggesting that the molecular changes leading to the growth advantage may occur downstream of MAPK/AKT signaling.
To further demonstrate a role of miR-378 in Mycdriven transformation, we employed a miRNA sponge Myc/miR-378/TOB2/cyclin D1 module regulates transformation M Feng et al technology (Ebert et al., 2007) in order to achieve a stable inhibition of miR-378. Expression of miR-378 sponge inhibitor led to significant growth inhibition in both MCF10A-MYC and SKBR3 cells, which is known to harbor MYC amplification (Figures 3e and f). Collectively, these data clearly suggest an oncogenic role of miR-378 activated by Myc in promoting cellular transformation in the context of Ras or HER2 activation.
Tumor suppressor candidate TOB2 is a functional target of miR-378 To identify functional targets of miR-378, we performed the TargetScan analysis (http://www.targetscan.org). Among 107 putative targets of miR-378, TOB2, a member of anti-proliferative BTG protein family (Yoshida et al., 2003; Winkler, 2010) , was top ranked, and its 3 0 UTR contains two highly conserved miR-378-binding sites or miRNA responsive element ( Figure 4a ). Given that the closely related family member TOB1 has been previously shown to inhibit cellular growth (Suzuki et al., 2002) , we postulate that miR-378 may execute its oncogenic activity through antagonizing a negative growth regulator and thus TOB2 may be such a candidate. We first tested whether TOB2 is a direct target of miR-378. Luciferase reporter assay was employed to detect the potential interaction of miR-378 with the 3 0 UTR of TOB2. The results showed that miR-378 repressed the luciferase activity of constructs containing either one of the predicted miR-378 miRNA responsive element sites but not the constructs containing the mutated miR-378-binding sites (Figure 4b ), supporting a direct inhibition of TOB2 by miR-378. As expected, miR-378 mimic treatment in MCF10A and MCF7 cells resulted in a marked decrease of TOB2 at both mRNA and protein levels, though TOB1 expression was not affected (Figure 4c ). Conversely, in breast cancer SKBR3 and MDA-MB-231 cells, an antagomir inhibitor of miR-378 was able to upregulate the expression of TOB2 protein or mRNA, again not TOB1 (Figure 4d ). Moreover, consistent with Myc upregulation of miR-378, Myc overexpression in MCF10A cells inhibited TOB2 expression (Figure 4e) , and conversely Myc knockdown in SKBR3 and MDA-MB-231 cells by three different siRNAs led to TOB2 induction ( Figure 4f and Supplementary Figure 3a) . The effect of miR-378 or Myc on TOB2 was unlikely to be a non-specific effect of altered cell proliferation, as TOB1, which is also a growth-related family member, was not affected in above treatments. In addition, all cells harvested for protein analysis at 48 h after transfection were still in active proliferating condition (Supplementary Figure 3b) . Therefore, both gain-and loss-of-function data validated an inhibitory effect of Myc-miR-378 on Myc/miR-378/TOB2/cyclin D1 module regulates transformation M Feng et al TOB2 expression and this effect was not a secondary effect of phenotypic change.
We next investigated whether TOB2 inhibition is sufficient to induce transformation. TOB2 knockdown by two independent small hairpin RNAs had little or no effect on HMLE cells but increased both anchoragedependent and -independent growth in HMLER cells (Figures 5a and b) . Again, MAPK or AKT was not activated in TOB2 knockdown cells (Supplementary Figure 3c) . This result mimics the effect of miR-378 and indicates that TOB2 loss also required oncogenic Ras to promote the transformation. Thus, TOB2 knockdown has phenocopied the miR-378 overexpression, supporting TOB2 to be a functional target of miR-378 in transformation. Moreover, retroviral expression of TOB2 diminished the growth and transforming capacity of MCF10A-MYC, HMLER-miR-378 or HMLE-HER2-miR-378 cells, but to a lesser extent in HMLER cells (Figures 5c and d) . Taken together, these results revealed a key role of TOB2 loss in Myc/miR-378-induced transformation and suggest that targeting and inhibiting TOB2 is attributable largely to the oncogenic function of miR-378.
TOB2 is a transcriptional repressor of cyclin D1 As miR-378 overexpression or TOB2 knockdown had no effect on MAPK or AKT signaling, we next sought to identify the downstream effector of MAPK/AKT that might be responsible for the increased transformation. It has been previously shown that cyclin D1, a known downstream effector of Ras-MAPK signaling, is transcriptionally repressed by TOB1 in a transgenic mouse model (Yoshida et al., 2003; Shapiro, 2006) . We thus tested whether TOB2 has a similar effect on cyclin D1 expression. We found that TOB2 knockdown gave rise to only a slight increase in cyclin D1 expression in HMLE cells, but a strong induction of cyclin D1 in HMLER cells (Figure 6a) . Conversely, TOB2 overexpression in HMLER-miR-378 or HMLE-HER2-miR-378 cells resulted in drastic downregulation of cyclin D1 Myc/miR-378/TOB2/cyclin D1 module regulates transformation M Feng et al (Figure 6b ). Echoing the TOB2 knockdown, miR-378 overexpression also increased cyclin D1 expression in HMLER or HMLE-HER2 cells, but not in HMLE cells (Figure 6c ). We further show that overexpression or knockdown of TOB2 was able to change cyclin D1 promoter luciferase reporter activity accordingly, and miR-378 overexpression induced cyclin D1 promoter activity in HMLER cells, but not in HMLE cells (Figure 6d ). Moreover, we show that TOB2 directly binds to the cyclin D1 promoter as assessed by chromatin immunoprecipitation assay using TOB2 antibody (Figure 6e ). We further provide evidence to show that the ability of TOB2 to inhibit cellular growth correlates with its inhibitory effect on cyclin D1. Expression levels of miR-378 and TOB2 were inversely correlated in MCF7 and SKBR3 cells (Figure 6f ). We show that ectopic TOB2 expression resulted in marked growth inhibition in SKBR3 cells that express a higher level of miR-378, but had no effect on MCF7 cells with a lower level of miR-378 (Figure 6g) . Notably, despite a higher level of TOB2 in MCF-7 cells, cyclin D1 expression remained to be high and resistant to suppression by TOB2 overexpression (Figure 6h ). This suggests that cyclin D1 in MCF7 cells is not subject to TOB2 regulation and its expression may be regulated mainly by other mechanisms. By contrast, in SKBR3 cells, TOB2 overexpression resulted in marked inhibition of cyclin D1 expression (Figure 6h ), corresponding to a strong growth inhibition effect of TOB2 in this cell line. Thus, the effect of TOB2 on cyclin D1 correlated with its growth inhibition effect. Taken together, our findings suggest a model in which Myc-miR-378-TOB2-cyclinD1 modules with Ras to promote transformation (Figure 6i ).
Discussion
We demonstrated a crucial role of miR-378 as a novel target of Myc in Myc-mediated transformation. miR-378 confers an oncogenic function by, at least in part, targeting and inhibiting TOB2, a tumor suppressor candidate and a transrepressor of cyclin D1. We show that miR-378 alone is insufficient but requires prerequisite alterations and in this case the oncogenic Ras or HER2 to promote transformation. Although Myc and Ras are known to be coordinated in tumorigenesis (D'Cruz et al., 2001; Kendall et al., 2005) , the genetic elements involved in the cross talk between the two oncogene pathways are 
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shTOB2 : Myc/miR-378/TOB2/cyclin D1 module regulates transformation M Feng et al still under extensive investigation to date. Our finding that miR-378-induced TOB2 loss upon Myc activation cooperates with Ras signaling provides a possible mechanism that underlies the cooperation between these two important oncogenic pathways. A cross talk between Myc and Ras can be mediated through Ras effector pathways, including Raf-MEK-ERK (extracellular signal-regulated kinases) kinase cascade, and the PI3K-Akt pathway that inhibits GSK3b, leading to increased Myc phosphorylation and activity (Sears et al., 2000) . We show here that a distinct mechanism may operate that does not involve the MAPK or AKT signaling but occurs at the promoter of cyclin D1, which is a known downstream target of Ras-MAPK pathway (Stacey and Kazlauskas, 2002) . TOB2 inhibits cyclin D1 transcription by directly binding to the cyclin D1 promoter. Like miR-378 overexpession, TOB2 knockdown synergizes with Ras signaling to promote cyclin D1 transcription and transformation. Although TOB1 is also known to inhibit cyclin D1 expression, it does not seem to be regulated by Myc-miR-378. Thus, our data provides a model in which Myc-miR-378-TOB2 and Ras-ERK signaling pathways converge on the cyclin D1 level to promote transformation. Cyclin D1 is an important proto-oncogene whose expression is tightly regulated by multiple mechanisms. While multiple oncogenic signaling pathways activate cyclin D1 expression, TOB2 acts to inhibit it, thus providing an antagonism mechanism to control the cyclin D1 expression. Our data provides novel insights into cyclin D1 expression regulation and it also indicates that during tumorigenesis, this regulation may be disrupted because of Myc-induced miR-378 expression. Thus, identification of key molecular antagonism governing the transcriptional output of a key growth signal is important to understand its homeostasis regulation as well as its deregulation in a disease process. Our findings further underscore the important roles of miRNAs in oncogenesis through navigating multiple signaling networks in order to achieve maximum functional output or to antagonize unfavorable response.
Materials and methods
Cell culture and transfection MCF10A, SKBR3, MCF7, BT-549, MDA-MB-231 and HEK293T cells were purchased from American Type Culture Collection. SKBR3 cells were maintained in McCoy's 5A medium whereas all other cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. HMLE and HMLER cells are generous gift from Dr Hahn, W.C (Dana-Farber Cancer Institute, Boston, MA, USA). HMLE, MCF10A and derivatives were cultured in MEGM Lonza Group Ltd, Basel, Switzerland) . Oligo miRNA mimics and antagomirs were purchased from Dharmacon, Inc. (Chicago, IL, USA). siRNA sequence against TOB2 were customer-designed by 1st BASE Singapore (#1, GGUCGC AAGUCCUUAUUUAUU; #2, GUCCGUUUGUAUUG AAUAAUU), siRNA against c-Myc #1 & #2 were referenced from Cappellen et al. (2007) , whereas #3 was purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). For transfection, siRNAs (50 nM final concentration), miRNA mimics (1-50 nM concentration) or miRNA antagomirs (100 nM final concentration) were transfected into appropriate cells using lipofectamine RNAimax (Invitrogen Singapore Pte Ltd, Singapore), 48 h after transfection cell pellets were collected and subject to RNA isolation and immunoblot analysis.
DNA constructs and stable cell line construction c-Myc and its binding mutant dMbI (d41-66) and dMbII (d128-143) in pBabeMNiresGFP (pMN) constructs were provided by LZ Penn (University of Toronto, Ontario, Cannada). The human miR-378 gene including approximately 200 bp upstream and 200 bp downstream the stemloop structure was PCR-amplified from genomic DNA and cloned into XhoI and EcoRI sites MDH1-PGK-GFP_2.0 retroviral vector (Addgene Cat No. 11375, Addgene Inc., Cambridge, MA, USA). Human TOB2 gene coding region was PCR amplified from normal colon c-DNA and sub-cloned into pBabe-Puro vector using BamHI and XhoI sites, while TOB2 3 0 UTR fragments surrounding the miR-378 the miRNA responsive elements (miRNA response element) approximately 400 bp in length were cloned into SpeI and SacI site of pMIR-REPORT luciferase vector immediately downstream of firefly luciferase gene (Applied Biosystems B.V., Chromos, Singapore). Site-directed mutagenesis reactions were carried using GeneTailor Site-Directed Mutagenesis System (Invitrogen). The miR-378 and CCND1 promoter constructs were constructed by ligating the respective PCR products into a promoter-less vector pGL4 basic (Promega) upstream of firefly luciferase gene employing appropriate restriction sites. The miR-378-F1 promoter construct encompasses þ 1 to þ 2400 region directly after the transcription start site, whereas the negative control F2 plasmid contains À1500 to À500 sequence upstream of the transcription start site site. The CCND1 promoter construct contains genomic region spanning À1646 to þ 214 of the CCND1 transcription start site site. TOB2 small hairpin RNA constructs were generated by inserting two independent siRNA hairpin oligo-nucleotides into pSIREN-RetroQ (Clontech Laboratories, Inc., Mountain View, CA, USA). miRNA sponge constructs namely SP-NC and SP-miR-378 were constructed by inserting 10 copies of miRNA antisense Oligos in tandem into pBabe retroviral vectors (Ebert et al., 2007) . All plasmid sequences were verified free of mutation by direct sequencing. The sequences of all primers are provided in Supplementary  Table 3 . All stable cell lines were generated via retroviral infection using HEK293T cells, as has been previously described (Tan et al., 2007; Yang et al., 2009 ). For GFP-based vectors, fluorescence-activated cell sorting was employed to eliminate non-expressing cells; for pBabe-based vectors, puromycin was added to growth medium at a final concentration of 2 mg/ml. miRNA expression array analysis Agilent Human miRNA Microarray Kit V3 (G4470C, Agilent Technologies Singapore (sales) Pte Ltd, Singapore), which contains probes for 866 human from the Sanger database v12.0, was employed in our study. Total RNA, including miRNA, was extracted from cells using a mirVana miRNA Isolation Kit (Ambion, Austin, TX, USA) according to the manufacturer's instructions and quantified with Agilent Small RNA Kit using 2100 bioanalyzer (Agilent Technologies). For hybridization, 100 ng total RNA was dephosphorylated with calf intestine alkaline phosphatase, denatured with dimethyl sulfoxide, and labeled with pCp-Cy3 using T4 RNA ligase (Agilent miRNA complete labeling and Hyb Kit). The labeled RNAs were hybridized to Agilent human miRNA microarray kit. After hybridization and washing, the arrays were scanned with Agilent microarray scanner using high dynamic range settings as specified by the manufacturer. Agilent Feature Extraction Software was used to extract the raw intensity data that were further analyzed using GeneSpring GX software (Agilent Technologies).
Quantitative reverse transcription-PCR TaqMan MicroRNA assays were used to quantify the level of mature miRNAs as previously described (Tan et al., 2007; Yang et al., 2009) . Briefly, 10 ng of total RNA was reverse transcribed and product was subjected to TaqMan stemloop miRNA assay (Applied Biosysterms). Reactions were analyzed in an Applied Biosystems 7900HT Fast Real-Time PCR system in 96-well plate format. RNU6B was used to normalize the data. For quantification of mRNA levels, gene specific TaqMan probe to PPARGC1B, MYC, CCND1, TOB2 were purchased from ABI (Applied Biosystems). GAPDH mRNA level was used as internal control in all gene expression TaqMan measurements.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assays were performed as described previously (Jiang et al., 2008) utilizing TOB2 mouse monoclonal antibody (WH0010766M1, Sigma) or mouse IgG as non-specific control. Immunoprecipitated DNA was quantified by real-time quantitative PCR using ABI 7900HT system. Primer sets were chosen to amplify 100 to 120 bp of the indicated regions. The enrichment of TOB2 binding at examined regions was quantified relative to the input amount. The resulting percentage of input values were further normalized to the dCt values against a region that shows very low background TOB2 specific binding to obtain relative fold of enrichment for both TOB2 antibody and IgG control. The sequences of the primers are shown in Supplementary Table 3 .
Immunoblot analysis
For miRNA mimics or antagomir or siRNA treated cells, 48 h after transfection cell pellets were collected for Immunoblot analysis following standard protocol was done as previously described (Jiang et al., 2008) . The following antibodies were utilized in our study: TOB2 (WH0010766M1), TOB1 (T2948), b-Actin (A5441) from Sigma-Aldrich, St Louis, MO, USA, cyclin D1(M20) from Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA; Ras (3965), HER2(2248), pERK (9101), ERK (9102), pMEK (9121), MEK (9122), pAKT (9271), ATK (9272), Myc (9402) from Cell Signaling Technologies.
Luciferase assays HEK293T cells were plated at a density of 5 Â 10 4 cells per well in 24-well plate format and co-transfected with 100 ng pGL4 vectors containing miR-378 promoters and 100 ng of c-Myc expression vector pcDNA4 (Invitrogen) or pGL4 constructs containing CCND1 promoters and TOB2 expression plamids, respectively. At 48 h after transfection, the luciferase activities were measured using the Dual Luciferase system (Promega Pte Ltd, Singapore Science Park I, Singapore). For miRNAmediated gene repression assays, similar experimental set up was employed apart from that 10 ng of pMIR REPORT containing respective miRNA responsive elements and UTRs and 40 nM of miRNA mimics were utilized in our study. pRL null Renilla luciferase vector was employed as internal control all through our reporter assays. All luciferase readings were first normalized to corresponding internal control pRL null Renilla luciferase readings, the resulting relative activities were further normalized to appropriate non-specific controls as indicated in figure legend. Three independent assays were plotted using GraphPad Prism software.
Soft agar assay and monolayer colony formation assay Exponentially growing stable cell lines or transfected cells 48 h post miRNA mimics or antagomirs treatment were plated in triplicates in appropriate medium containing 0.3% Bacto-agar on top of 0.6% bottom agar and cultured for 2 weeks. Colonies were visualized by 0.1% p-iodonitro tetrazolium violet (INT, Sigma) staining. For monolayer colony formation assay, 1000 cells either stably express virus delivered genes or 48 h post miRNA or antagomirs treatment were plated in 6-well plates in triplicate and allowed to grow in appropriate culture medium for 2 weeks. Fresh media were supplied every 3 days. Colonies were stained with crystal violet dye after methanol fixation.
Cell viability assay
Cell viability was determined using CellTiter-Glo Luminescent Cell Viability Assay (Promega) as instructed by manufacturer's manual. Equal number of 1000 cells of stable cell lines or transfected cells 48 h post miRNA mimics or antagomirs treatment were plated in triplicates in 96-well plate and the ATPase readings were taken 1-11 days according to the proliferation rate of individual cell lines.
Statistical analysis
We employed GraphPad Prism software to conduct statistical analysis. Results are expressed as the mean ± s.e.m. For Pvalue calculation, unpaired student's T tests (two tailed) were utilized for all comparisons. P-values o0.05 were considered as significant.
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